Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence
- PMID: 2033387
- DOI: 10.1099/0022-1317-72-5-1031
Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence
Abstract
Different passages of the vaccinia virus strain Ankara (CVA wild-type) during attenuation to MVA (modified vaccinia virus Ankara) have been analysed to detect alterations in the genome. Physical maps for the restriction enzymes HindIII and XhoI have been established. Six major deletions relative to the wild-type strain CVA could be localized. They reduce the size of the entire genome from 208 kb (CVA wild-type) to 177 kb for the MVA strain. Four deletions occurred during the first 382 passages and the resulting variant (CVA 382) displays an attenuated phenotype similar to that of the MVA strain. The deletions are located in both terminal fragments, affect two-thirds of the host range gene K1L and eliminate 3.5 kb of a highly conserved region in the HindIII A fragment. During the next 190 passages leading to MVA two additional deletions appeared. Again, one is located in the left terminal fragment, and the other includes the A-type inclusion body gene. Neither of the deletions appear to participate in further attenuation of the virus. Rescue of the partially deleted host range region with the corresponding wild-type DNA restored the ability of the attenuated strains MVA and CVA 382 to grow in some non-permissive tissue cultures. Nevertheless, the complete host range of the wild-type strain was not recovered. Also, plaque-forming behaviour and reduced virulence were not influenced. From the data presented it may be concluded that the partially deleted host range gene is not solely responsible for attenuation.
Similar articles
-
Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.J Virol. 2010 Oct;84(19):9907-19. doi: 10.1128/JVI.00756-10. Epub 2010 Jul 28. J Virol. 2010. PMID: 20668072 Free PMC article.
-
Marker rescue of the host range restriction defects of modified vaccinia virus Ankara.Virology. 1998 Nov 25;251(2):334-42. doi: 10.1006/viro.1998.9397. Virology. 1998. PMID: 9837798
-
The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses.Virology. 1998 May 10;244(2):365-96. doi: 10.1006/viro.1998.9123. Virology. 1998. PMID: 9601507 Review.
-
Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line.Virology. 1997 Nov 24;238(2):198-211. doi: 10.1006/viro.1997.8845. Virology. 1997. PMID: 9400593
-
Virulence genes of poxviruses and reoviruses.Vaccine. 1988 Apr;6(2):123-8. doi: 10.1016/s0264-410x(88)80013-6. Vaccine. 1988. PMID: 2838983 Review.
Cited by
-
Whole genome sequencing of recombinant viruses obtained from co-infection and superinfection of Vero cells with modified vaccinia virus ankara vectored influenza vaccine and a naturally occurring cowpox virus.Front Immunol. 2024 Apr 3;15:1277447. doi: 10.3389/fimmu.2024.1277447. eCollection 2024. Front Immunol. 2024. PMID: 38633245 Free PMC article.
-
Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection.Viruses. 2024 Mar 8;16(3):417. doi: 10.3390/v16030417. Viruses. 2024. PMID: 38543782 Free PMC article.
-
Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages.Front Immunol. 2024 Feb 6;15:1338492. doi: 10.3389/fimmu.2024.1338492. eCollection 2024. Front Immunol. 2024. PMID: 38380318 Free PMC article.
-
Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8.PLoS Negl Trop Dis. 2023 Dec 15;17(12):e0011851. doi: 10.1371/journal.pntd.0011851. eCollection 2023 Dec. PLoS Negl Trop Dis. 2023. PMID: 38100536 Free PMC article.
-
A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.Mol Ther Methods Clin Dev. 2023 Sep 16;31:101110. doi: 10.1016/j.omtm.2023.101110. eCollection 2023 Dec 14. Mol Ther Methods Clin Dev. 2023. PMID: 37822719 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources